• Something wrong with this record ?

Engine shutdown: migrastatic strategies and prevention of metastases

M. Raudenská, K. Petrláková, T. Juriňáková, J. Leischner Fialová, M. Fojtů, M. Jakubek, D. Rösel, J. Brábek, M. Masařík

. 2023 ; 9 (4) : 293-308. [pub] 20230215

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc23003652

Most cancer-related deaths among patients with solid tumors are caused by metastases. Migrastatic strategies represent a unique therapeutic approach to prevent all forms of cancer cell migration and invasion. Because the migration machinery has been shown to promote metastatic dissemination, successful migrastatic therapy may reduce the need for high-dose cytotoxic therapies that are currently used to prevent the risk of metastatic dissemination. In this review we focus on anti-invasive and antimetastatic strategies that hold promise for the treatment of solid tumors. The best targets for migrastatic therapy would be those that are required by all forms of motility, such as ATP availability, mitochondrial metabolism, and cytoskeletal dynamics and cell contractility.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003652
003      
CZ-PrNML
005      
20230425140800.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.trecan.2023.01.001 $2 doi
035    __
$a (PubMed)36804341
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Raudenská, Martina $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic
245    10
$a Engine shutdown: migrastatic strategies and prevention of metastases / $c M. Raudenská, K. Petrláková, T. Juriňáková, J. Leischner Fialová, M. Fojtů, M. Jakubek, D. Rösel, J. Brábek, M. Masařík
520    9_
$a Most cancer-related deaths among patients with solid tumors are caused by metastases. Migrastatic strategies represent a unique therapeutic approach to prevent all forms of cancer cell migration and invasion. Because the migration machinery has been shown to promote metastatic dissemination, successful migrastatic therapy may reduce the need for high-dose cytotoxic therapies that are currently used to prevent the risk of metastatic dissemination. In this review we focus on anti-invasive and antimetastatic strategies that hold promise for the treatment of solid tumors. The best targets for migrastatic therapy would be those that are required by all forms of motility, such as ATP availability, mitochondrial metabolism, and cytoskeletal dynamics and cell contractility.
650    _2
$a lidé $7 D006801
650    12
$a nádory $x farmakoterapie $7 D009369
650    _2
$a pohyb buněk $7 D002465
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Petrláková, Kateřina $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic
700    1_
$a Juriňáková, Tamara $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic
700    1_
$a Leischner Fialová, Jindřiška $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic
700    1_
$a Fojtů, Michaela $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic
700    1_
$a Jakubek, Milan $u BIOCEV (Biotechnology and Biomedicine Center in Vestec), First Faculty of Medicine, Charles University, Prumyslova 595, CZ-252 50 Vestec, Czech Republic
700    1_
$a Rösel, Daniel $u Department of Cell Biology, BIOCEV, Faculty of Science, Charles University, CZ-252 50, Vestec, Prague-West, Czech Republic
700    1_
$a Brábek, Jan $u Department of Cell Biology, BIOCEV, Faculty of Science, Charles University, CZ-252 50, Vestec, Prague-West, Czech Republic
700    1_
$a Masařík, Michal $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic; BIOCEV (Biotechnology and Biomedicine Center in Vestec), First Faculty of Medicine, Charles University, Prumyslova 595, CZ-252 50 Vestec, Czech Republic. Electronic address: masarik@med.muni.cz
773    0_
$w MED00195479 $t Trends in cancer $x 2405-8025 $g Roč. 9, č. 4 (2023), s. 293-308
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36804341 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140756 $b ABA008
999    __
$a ok $b bmc $g 1924370 $s 1189861
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 9 $c 4 $d 293-308 $e 20230215 $i 2405-8025 $m Trends in cancer $n Trends Cancer $x MED00195479
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options